View : 688 Download: 228
Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation–related mild ischemic stroke: A randomized clinical trial
- Title
- Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation–related mild ischemic stroke: A randomized clinical trial
- Authors
- Hong K.-S.; Kwon S.U.; Lee S.H.; Lee J.S.; Kim Y.-J.; Song T.-J.; Kim Y.D.; Park M.-S.; Kim E.-G.; Cha J.-K.; Sung S.M.; Yoon B.-W.; Bang O.Y.; Seo W.-K.; Hwang Y.-H.; Ahn S.H.; Kang D.-W.; Kang H.G.; Yu K.-H.
- Ewha Authors
- 김용재; 송태진
- SCOPUS Author ID
- 김용재; 송태진
- Issue Date
- 2017
- Journal Title
- JAMA Neurology
- ISSN
- 2168-6149
- Citation
- JAMA Neurology vol. 74, no. 10, pp. 1206 - 1215
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- IMPORTANCE: In atrial fibrillation (AF)–related acute ischemic stroke, the optimal oral anticoagulation strategy remains unclear. OBJECTIVE: To test whether rivaroxaban or warfarin sodium is safer and more effective for preventing early recurrent stroke in patients with AF-related acute ischemic stroke. DESIGN, SETTING, AND PARTICIPANTS: A randomized, multicenter, open-label, blinded end point evaluation, comparative phase 2 trial was conducted from April 28, 2014, to December 7, 2015, at 14 academic medical centers in South Korea among patients with mild AF-related stroke within the previous 5 days who were deemed suitable for early anticoagulation. Analysis was performed on a modified intent-to-treat basis. INTERVENTIONS: Participants were randomized 1:1 to receive rivaroxaban, 10 mg/d for 5 days followed by 15 or 20 mg/d, or warfarin with a target international normalized ratio of 2.0-3.0, for 4 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was the composite of new ischemic lesion or new intracranial hemorrhage seen on results of magnetic resonance imaging at 4 weeks. Primary analysis was performed in patients who received at least 1 dose of study medications and completed follow-up magnetic resonance imaging. Key secondary end points were individual components of the primary end point and hospitalization length. RESULTS: Of 195 patients randomized, 183 individuals (76 women and 107 men; mean [SD] age, 70.4 [10.4] years) completed magnetic resonance imaging follow-up and were included in the primary end point analysis. The rivaroxaban group (n = 95) and warfarin group (n = 88) showed no differences in the primary end point (47 [49.5%] vs 48 [54.5%]; relative risk, 0.91; 95% CI, 0.69-1.20; P = .49) or its individual components (new ischemic lesion: 28 [29.5%] vs 31 of 87 [35.6%]; relative risk, 0.83; 95% CI, 0.54-1.26; P = .38; new intracranial hemorrhage: 30 [31.6%] vs 25 of 87 [28.7%]; relative risk, 1.10; 95% CI, 0.70-1.71; P = .68). Each group had 1 clinical ischemic stroke, and all new intracranial hemorrhages were asymptomatic hemorrhagic transformations. Hospitalization length was reduced with rivaroxaban compared with warfarin (median, 4.0 days [interquartile range, 2.0-6.0 days] vs 6.0 days [interquartile range, 4.0-8.0]; P < .001). CONCLUSIONS AND RELEVANCE: In mild AF-related acute ischemic stroke, rivaroxaban and warfarin had comparable safety and efficacy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02042534. © 2017 American Medical Association. All rights reserved.
- DOI
- 10.1001/jamaneurol.2017.2161
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
-
Rivaroxaban vs warfarin.pdf(309.41 kB)
Download
- Export
- RIS (EndNote)
- XLS (Excel)
- XML